Design Therapeutics Stock Probability of Future Stock Price Finishing Over 18.79
| DSGN Stock | USD 6.21 0.04 0.64% |
Design |
Design Therapeutics Target Price Odds to finish over 18.79
The tendency of Design Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 18.79 or more in 90 days |
| 6.21 | 90 days | 18.79 | close to zero percent |
Based on a normal probability distribution, the odds of Design Therapeutics to move over $ 18.79 or more in 90 days from now is close to zero percent (This Design Therapeutics probability density function shows the probability of Design Stock to fall within a particular range of prices over 90 days) . Probability of Design Therapeutics price to stay between its current price of $ 6.21 and $ 18.79 at the end of the 90-day period is about 19.02 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.67 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Design Therapeutics will likely underperform. Additionally Design Therapeutics has an alpha of 0.1856, implying that it can generate a 0.19 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Design Therapeutics Price Density |
| Price |
Predictive Modules for Design Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Design Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Design Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Design Therapeutics is not an exception. The market had few large corrections towards the Design Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Design Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Design Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.19 | |
β | Beta against Dow Jones | 2.67 | |
σ | Overall volatility | 0.57 | |
Ir | Information ratio | 0.04 |
Design Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Design Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Design Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Design Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (66.86 M) with loss before overhead, payroll, taxes, and interest of (48.61 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (58.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Design Therapeutics SWOT analysis geneTAC stock faces early-stage hurdles |
Design Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Design Stock often depends not only on the future outlook of the current and potential Design Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Design Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56 M | |
| Cash And Short Term Investments | 281.8 M |
Design Therapeutics Technical Analysis
Design Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Design Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Design Therapeutics. In general, you should focus on analyzing Design Stock price patterns and their correlations with different microeconomic environments and drivers.
Design Therapeutics Predictive Forecast Models
Design Therapeutics' time-series forecasting models is one of many Design Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Design Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Design Therapeutics
Checking the ongoing alerts about Design Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Design Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Design Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (66.86 M) with loss before overhead, payroll, taxes, and interest of (48.61 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (58.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Design Therapeutics SWOT analysis geneTAC stock faces early-stage hurdles |
Check out Design Therapeutics Backtesting, Design Therapeutics Valuation, Design Therapeutics Correlation, Design Therapeutics Hype Analysis, Design Therapeutics Volatility, Design Therapeutics History as well as Design Therapeutics Performance. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.